Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Envisia Therapeutics Inc.

Betting implants can best eyedrops in glaucoma

This article was originally published in Start Up

Executive Summary

Envisia Therapeutics Inc. is betting that a proprietary method of engineering micro- and nanoparticles of precise size, shape, and chemistry will enable it to develop drugs for direct delivery to various compartments of the eye. The start-up, formed in November 2013 as a spin-out from Liquidia Technologies Inc., has licensed rights to the parent company's Particle Replication in Non-wetting Templates (PRINT) technology to create new ocular therapies.


Related Content


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts